Mylan Launches First Generic Version of Xopenex Inhalation Solution

Mylan has announced that its subsidiary Mylan Pharmaceuticals has launched levalbuterol inhalation solution, 0.25%, (1.25mg/0.5ml). Mylan, which has already launched the product, will market this product with 180 days of exclusivity.

This product, which is indicated for the treatment or prevention of bronchospasm in patients over 6 years old with reversible obstructive airway disease, is the first generic version of Sepracor’s Xopenex Inhalation Solution, 0.25%, to be approved by the FDA.

Mylan is a specialty pharmaceutical company, and manufacturer of prescription generic drugs. It is foccused on antibiotics, antidepressants, anti-inflammatories, and laxatives.